Cantor Fitzgerald Reiterates Overweight on ACADIA Pharmaceuticals, Maintains $42 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on ACADIA Pharmaceuticals (ACAD) and maintained a $42 price target.
February 28, 2024 | 4:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on ACADIA Pharmaceuticals with a $42 price target.
The reiteration of an Overweight rating and the maintenance of a $42 price target by a reputable analyst could positively influence investor sentiment towards ACADIA Pharmaceuticals. This endorsement may lead to increased investor confidence in the stock, potentially driving its price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100